Renal cell adenocarcinoma

This study tests whether adding a virus-based drug (pelareorep) to standard chemotherapy can help people with a specific type of advanced colorectal cancer that has stopped responding to initial treatment. About 60 adults whose cancer has spread and has certain genetic features (…

This phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…

This study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer drugs. About 224 participants who have not had prior treatment for their advanced…

This Phase 3 trial is testing whether adding the drug zanzalintinib to belzutifan helps people with advanced kidney cancer live longer and keep the cancer from growing. About 758 participants who have already tried standard treatments will receive either the combination or belzut…

This pilot phase II trial tests whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for patients with high-risk clear cell kidney cancer that hasn't spread. Sixteen participants will receive the drugs and then undergo surgery …

This early-stage trial is testing a drug called orellanine, derived from a mushroom, in 75 people with advanced kidney cancer who are also on dialysis. The drug is given intravenously to see if it is safe and can shrink tumors. All participants have end-stage kidney disease and h…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This phase 2 trial is testing whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can safely shrink or stabilize advanced kidney cancer in people with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. The dr…

This study tests the safety and effectiveness of a treatment called radioembolization for people with early stage kidney cancer. Tiny glass spheres containing radioactive yttrium-90 are injected into the artery feeding the tumor to destroy it from inside. The trial will enroll 25…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests whether analyzing the genes of a kidney tumor can help doctors pick the best drug combination for each patient. Participants with advanced or metastatic clear cell kidney cancer will receive either two immunotherapy drugs (nivolumab plus ipilimumab) or one immuno…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug bef…

This study tests whether adding inulin gel, a fiber supplement, to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer. About 55 adults with metastatic or locally advanced clear cell or sarcomatoid kidney cancer will take part. Research…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This early-phase trial tests whether adding a live bacteria supplement (EXL01) to standard immunotherapy (nivolumab and ipilimumab) is safe and more effective for people with metastatic kidney cancer. About 33 participants will receive either the immunotherapy alone or with the s…

This study tests a combination of two treatments for people with localized clear cell kidney cancer that can be surgically removed. The first is a personalized vaccine made from the patient's own immune cells, designed to target proteins found on tumor blood vessels. The second i…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This phase 3 trial tests whether adding a live biotherapy called MO-03 to standard immunotherapy can help control advanced or metastatic clear cell renal cell carcinoma. MO-03 is designed to improve gut health, which may make immunotherapy work better. About 718 participants will…

This phase 2 trial tests whether adding a live bacteria product called CBM588 to the immunotherapy drug pembrolizumab can help prevent kidney cancer from coming back after surgery. About 62 adults with high-risk clear cell or sarcomatoid kidney cancer will receive either pembroli…

This phase 2 trial tests whether adding a lab-modified virus (VSV-IFNβ-NIS) to standard immunotherapy drugs (ipilimumab and nivolumab) can shrink tumors in people with advanced or metastatic clear cell kidney cancer. The virus is designed to kill cancer cells without harming norm…

This study tests whether adding bicalutamide (a prostate cancer drug) to sunitinib (a standard kidney cancer drug) can help people whose kidney cancer has stopped responding to other targeted therapies. The trial will enroll 28 adults with advanced renal cell carcinoma. Researche…

This study looks at how well the drug vorolanib works for people with advanced kidney cancer that cannot be removed by surgery or has spread. It is for patients who need a second treatment after their first one stopped working. The study will track how long the cancer stays under…

This phase III trial is testing whether adding surgery to remove the kidney (nephrectomy) to standard immunotherapy drugs helps people with kidney cancer that has spread live longer. About 364 participants will either receive immunotherapy alone or immunotherapy plus surgery. The…

This study is testing whether a protein called NMAP, measured in a blood sample, can help tell apart people with newly diagnosed kidney cancer from those without cancer. Researchers will compare NMAP levels in about 400 adults — half with kidney cancer and half without — to see h…

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…

This Phase II trial tests whether a special PET/CT scan using a radioactive tracer called 89Zr-DFO-girentuximab can find recurrent clear cell renal cell carcinoma after surgery better than standard contrast-enhanced CT. The tracer attaches to a protein (CAIX) on kidney cancer cel…

This study is testing whether a computer program (deep learning) can accurately tell the difference between early-stage (T1-T2) and more advanced (T3) kidney cancer on CT scans. Researchers will train the AI on 1,000 patients' scans and check its accuracy. If it works, the tool c…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…